Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study

The Lancet Neurology

Volumn 12, Issue 4, 2013, Pages 357-367

  Villemagne, Victor L ^a,b   Burnham, Samantha ^c   Bourgeat, Pierrick ^c   Brown, Belinda ^d   Ellis, Kathryn A ^b   Salvado, Olivier ^c   Szoeke, Cassandra ^b,e   Macaulay, S Lance ^c   Martins, Ralph ^d   Maruff, Paul ^f   Ames, David ^e   Rowe, Christopher C ^a,b   Masters, Colin L ^b  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c CSIRO   (Australia)

^d EDITH COWAN UNIVERSITY   (Australia)

^e NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^f National Ageing Research Institute ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; CARBON 11; PITTSBURGH COMPOUND B;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN CORTEX; BRAIN REGION; COGNITION; CONTROLLED STUDY; DEMENTIA; FEMALE; FOLLOW UP; HIPPOCAMPUS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; COGNITION DISORDERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; PROSPECTIVE STUDIES;

EID: 84875250937     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70044-9     Document Type: Article

References (35)

1. Blennow K, Zetterberg H, Rinne JO, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 2012, 69:1002-1010. the AAB-001201/202 Investigators.
2. Uenaka K, Nakano M, Willis BA, et al. Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease. Clin Neuropharmacol 2012, 35:25-29.
3. Sperling RA, Jack CR, Aisen PS Testing the right target and right drug at the right stage. Sci Transl Med 2011, 3(111). 111cm33.
4. Jack CR, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012, 71:765-775.
5. Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128.
6. Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013, 12:207-216.
7. Price JL, McKeel DW, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009, 30:1026-1036.
8. Price JL, Morris JC Tangles and plaques in nondemented aging and " preclinical" Alzheimer's disease. Ann Neurol 1999, 45:358-368.
9. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008, 65:1509-1517.
10. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452.
11. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010, 31:1275-1283.
12. Chételat G, Villemagne VL, Villain N, et al. Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology 2012, 78:477-484. the AIBL Research Group.
13. Lim YY, Pietrzak RH, Ellis KA, et al. Rapid Decline in Episodic Memory in Healthy Older Adults with High Amyloid-beta. J Alzheimers Dis 2012, 10.3233/JAD-2012-121516.
14. Villemagne VL, Pike KE, Chételat G, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 2011, 69:181-192.
15. 11C]Pittsburgh compound B data. Ann Neurol 2011, 70:857-861.
16. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012, 367:795-804. the Dominantly Inherited Alzheimer Network.
17. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56:303-308.
18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
19. Ellis KA, Bush AI, Darby D, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 2009, 21:672-687. the AIBL Research Group.
20. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007, 130:2837-2844.
21. Greiner M, Sohr D, Göbel P A modified ROC analysis for the selection of cut-off values and the definition of intermediate results of serodiagnostic tests. J Immunol Methods 1995, 185:123-132.
22. Bourgeat P, Chételat G, Villemagne VL, et al. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010, 74:121-127. the AIBL Research Group.
23. Villain N, Chételat G, Grassiot B, et al. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain 2012, 135:2126-2139. the AIBL Research Group.
24. Jack CR, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010, 133:3336-3348. the Alzheimer's Disease Neuroimaging Initiative.
25. Akaike H Information theory and an extension of the maximum likelihood principle. Second International Symposium on Information Theory; 1973 1973, 267-281. Akademiai Kiado, Budapest. B.N. Petrov, F. Csaki (Eds.).
26. Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 2006, 63:674-681.
27. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010, 9:1118-1127.
28. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:270-279.
29. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:263-269.
30. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:280-292.
31. Tractenberg RE, Pietrzak RH Intra-individual variability in Alzheimer's disease and cognitive aging: definitions, context, and effect sizes. PLoS ONE 2011, 6:e16973.
32. Rowe CC, Villemagne VL Brain amyloid imaging. J Nucl Med 2011, 52:1733-1740.
33. Karran E, Mercken M, De Strooper B The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011, 10:698-712.
34. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010, 9:363-372.
35. Mueller SG, Weiner MW, Thal LJ, et al. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am 2005, 15:869-877. xi-xii.